Literature DB >> 34415386

Bone marrow tracer uptake pattern of PET-CT in multiple myeloma: image interpretation and prognostic value.

Jing Li1, Hui Tan2,3, Tianhong Xu1, Hongcheng Shi4,5, Peng Liu6.   

Abstract

PURPOSE: To evaluate the prognostic value of bone marrow (BM) imaging pattern and other imaging findings assessed by 18F-FDG PET-CT in multiple myeloma(MM) and to find out the image interpretation cut-off to define different BM tracer uptake pattern.
MATERIALS AND METHODS: We retrospectively studied PET-CT examinations and clinical data of 100 healthy individuals and 172 newly diagnosed MM patients. A BM uptake > liver SUVmean was selected as the positivity cut-off of pathological uptake in BM after comparing BM uptake in normal control and MM patients. With this interpretation cut-off, we defined the BM FDG uptake pattern as four types: normal, focal, diffuse, and mixed. The clinical correlation and prognostic value of BM uptake pattern were evaluated. The findings were validated in an independent prospective cohort with 72 MM patients.
RESULTS: In MM cohort, 34.9% patients had focal BM uptake pattern, 3.5% had diffuse pattern, 38.4% had mixed pattern, and 23.3% had normal BM uptake. Diffuse/mixed pattern was correlated with clinical and imaging parameters indicating high tumor burden, and inferior progression free survival (PFS; 3-year-PFS 26.8%) and overall survival (OS; 3-year-OS 50.6%). BM uptake pattern was an independent prognostic factor and diffuse/mixed pattern was associated with inferior OS (P = 0.037, HR 7.16) and PFS (P = 0.015, HR 7.77). The prognostic value of BM uptake pattern was also confirmed in validation set.
CONCLUSION: We propose an FDG uptake higher than liver as the positivity cut-off to discriminate between physiological and pathological uptake in BM and defined four BM FDG uptake pattern. BM FDG uptake pattern is a reliable prognostic predictor of MM.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Bone marrow; Image interpretation; Multiple myeloma; Positron emission tomography; Prognosis

Mesh:

Substances:

Year:  2021        PMID: 34415386     DOI: 10.1007/s00277-021-04629-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  28 in total

1.  Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data.

Authors:  Sarah Waheed; Alan Mitchell; Saad Usmani; Joshua Epstein; Shmuel Yaccoby; Bijay Nair; Rudy van Hemert; Edgardo Angtuaco; Tracy Brown; Twyla Bartel; James McDonald; Elias Anaissie; Frits van Rhee; John Crowley; Bart Barlogie
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

Review 2.  The multiple myelomas - current concepts in cytogenetic classification and therapy.

Authors:  Shaji K Kumar; S Vincent Rajkumar
Journal:  Nat Rev Clin Oncol       Date:  2018-07       Impact factor: 66.675

Review 3.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

4.  The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Authors:  Leo Rasche; Edgardo J Angtuaco; Terri L Alpe; Grant H Gershner; James E McDonald; Rohan S Samant; Manoj Kumar; Rudy Van Hemert; Joshua Epstein; Shayu Deshpande; Ruslana Tytarenko; Shmuel Yaccoby; Jens Hillengass; Sharmilan Thanendrarajan; Carolina Schinke; Frits van Rhee; Maurizio Zangari; Brian A Walker; Bart Barlogie; Gareth J Morgan; Faith E Davies; Niels Weinhold
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

5.  Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results.

Authors:  Cristina Nanni; Elena Zamagni; Mohsen Farsad; Paolo Castellucci; Patrizia Tosi; Delia Cangini; Eugenio Salizzoni; Romeo Canini; Michele Cavo; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02-02       Impact factor: 9.236

6.  Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

Authors:  James E McDonald; Marcus M Kessler; Michael W Gardner; Amy F Buros; James A Ntambi; Sarah Waheed; Frits van Rhee; Maurizio Zangari; Christoph J Heuck; Nathan Petty; Carolina Schinke; Sharmilan Thanendrarajan; Alan Mitchell; Antje Hoering; Bart Barlogie; Gareth J Morgan; Faith E Davies
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

7.  Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.

Authors:  Rosa Fonti; Michele Larobina; Silvana Del Vecchio; Serena De Luca; Rossella Fabbricini; Lucio Catalano; Fabrizio Pane; Marco Salvatore; Leonardo Pace
Journal:  J Nucl Med       Date:  2012-10-15       Impact factor: 10.057

8.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

9.  Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.

Authors:  Robert A Kyle; Dirk R Larson; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; James R Cerhan; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

10.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Authors:  Niccolo Bolli; Hervé Avet-Loiseau; David C Wedge; Peter Van Loo; Ludmil B Alexandrov; Inigo Martincorena; Kevin J Dawson; Francesco Iorio; Serena Nik-Zainal; Graham R Bignell; Jonathan W Hinton; Yilong Li; Jose M C Tubio; Stuart McLaren; Sarah O' Meara; Adam P Butler; Jon W Teague; Laura Mudie; Elizabeth Anderson; Naim Rashid; Yu-Tzu Tai; Masood A Shammas; Adam S Sperling; Mariateresa Fulciniti; Paul G Richardson; Giovanni Parmigiani; Florence Magrangeas; Stephane Minvielle; Philippe Moreau; Michel Attal; Thierry Facon; P Andrew Futreal; Kenneth C Anderson; Peter J Campbell; Nikhil C Munshi
Journal:  Nat Commun       Date:  2014       Impact factor: 14.919

View more
  1 in total

Review 1.  Metabolic Volume Measurements in Multiple Myeloma.

Authors:  Maria Emilia Seren Takahashi; Irene Lorand-Metze; Carmino Antonio de Souza; Claudio Tinoco Mesquita; Fernando Amorim Fernandes; José Barreto Campello Carvalheira; Celso Dario Ramos
Journal:  Metabolites       Date:  2021-12-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.